Verona Pharma PLC Director Dealing

 
TIDMVRP 
 
Verona Pharma plc 
                      ("Verona Pharma" or the "Company") 
 
                               Director Dealing 
 
3 December 2015, Cardiff - Verona Pharma plc (AIM: VRP) today received 
notification that David Ebsworth, Director of the Company, today purchased 
370,000 ordinary shares of 0.1 pence each of the Company ("Ordinary Shares") at 
a price of 3.25 pence per Ordinary Share. 
 
Following the transaction David Ebsworth has a total interest of 4,199,774 
Ordinary Shares, representing 0.42% of the total voting rights. 
 
                                    -Ends- 
 
For further information please contact: 
 
Verona Pharma plc                                     Tel: +44 (0) 20 3283 
                                                      4200 
 
Jan-Anders Karlsson, Chief Executive Officer 
 
N+1 Singer                                            Tel: +44 (0)20 7496 
                                                      3000 
 
Aubrey Powell / Jen Boorer 
 
FTI Consulting                                        Tel: +44 (0)20 3727 
                                                      1000 
 
Simon Conway / Stephanie Cuthbert / Natalie 
Garland-Collins 
 
Notes to Editors 
 
About Verona Pharma plc 
 
Verona Pharma plc is a UK-based clinical stage biopharmaceutical company 
focused on the development of innovative prescription medicines to treat 
respiratory diseases with significant unmet medical needs, such as chronic 
obstructive pulmonary disease (COPD), asthma and cystic fibrosis. 
 
Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase 
II trials as a nebulised treatment for acute exacerbations of COPD in the 
hospital setting.  The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and 
therefore has both bronchodilator and anti-inflammatory effects, which are 
essential to the improvement of patients with COPD and asthma. 
 
Verona Pharma is also building a broader portfolio of RPL554-containing 
products to maximise its benefit to patients and its value.  This includes the 
very significant markets for COPD and asthma maintenance therapy.  The Company 
is also exploring the potential of the drug in different diseases, such as 
cystic fibrosis, where it is in pre-clinical testing and has received a Venture 
and Innovation Award from the Cystic Fibrosis Trust. 
 
 
 
END

(END) Dow Jones Newswires

December 03, 2015 11:02 ET (16:02 GMT)

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024